Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07313579Recruiting

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

Role: lead

NCT07295236Recruiting

Impact of Endo-vac Therapy for Esophago-jejunal Anastomotic Leak

Role: lead

NCT06028737Phase 2Recruiting

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

Role: lead

NCT06755554Phase 3Recruiting

Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer

Role: lead

NCT04937738Phase 2Terminated

Perioperative Chemotherapy in Gastric Cancer

Role: lead

All 5 trials loaded